| Benjamin F Harris, OD | |
|
8436 Vaughn Rd, Montgomery, AL 36117-8862 | |
| (334) 271-3900 | |
| (334) 271-3915 |
| Full Name | Benjamin F Harris |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 30 Years |
| Location | 8436 Vaughn Rd, Montgomery, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326084906 | NPI | - | NPPES |
| 51058593 | Other | AL | BC |
| 000058593 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | S793TA189 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eyecare Associates, Inc. | 0749254001 | 56 |
News Archive
The Australian Cancer Research Foundation (ACRF) has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.
A large number of mouth cells exposed to e-cigarette vapor in the laboratory die within a few days, according to a study conducted by Université Laval researchers and published in the latest issue of Journal of Cellular Physiology.
Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.16 per ordinary share to $0.18 per ordinary share.
› Verified 6 days ago
| Provider Name | Jackson Laboratories |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1902902463 PECOS PAC ID: 0345135950 Enrollment ID: O20040220000723 |
News Archive
The Australian Cancer Research Foundation (ACRF) has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.
A large number of mouth cells exposed to e-cigarette vapor in the laboratory die within a few days, according to a study conducted by Université Laval researchers and published in the latest issue of Journal of Cellular Physiology.
Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.16 per ordinary share to $0.18 per ordinary share.
› Verified 6 days ago
| Provider Name | Eyecare Associates, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1710012877 PECOS PAC ID: 0749254001 Enrollment ID: O20040823000825 |
News Archive
The Australian Cancer Research Foundation (ACRF) has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.
A large number of mouth cells exposed to e-cigarette vapor in the laboratory die within a few days, according to a study conducted by Université Laval researchers and published in the latest issue of Journal of Cellular Physiology.
Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.16 per ordinary share to $0.18 per ordinary share.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin F Harris, OD 8436 Vaughn Rd, Montgomery, AL 36117-8862 Ph: (334) 271-3900 | Benjamin F Harris, OD 8436 Vaughn Rd, Montgomery, AL 36117-8862 Ph: (334) 271-3900 |
News Archive
The Australian Cancer Research Foundation (ACRF) has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.
A large number of mouth cells exposed to e-cigarette vapor in the laboratory die within a few days, according to a study conducted by Université Laval researchers and published in the latest issue of Journal of Cellular Physiology.
Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.16 per ordinary share to $0.18 per ordinary share.
› Verified 6 days ago
Dean Edward Schultz Iii, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 300 Twining St Bldg 760, Montgomery, AL 36112 Phone: 334-953-3368 Fax: 334-953-8607 | |
Dr. Camtu H. Nguyen, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 6495 Atlanta Hwy, Montgomery, AL 36117 Phone: 334-272-0124 | |
Montgomery Eye Physicians P.c Optometrist Medicare: Not Enrolled in Medicare Practice Location: 8131 Seaton Pl, Montgomery, AL 36116 Phone: 334-323-1889 Fax: 334-270-3375 | |
Dr. Stephen J. Bordlee, D.O. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 215 Perry Hill Rd, Montgomery, AL 36109 Phone: 334-270-4670 | |
Montgomery Optometric Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5783 Carmichael Pkwy, Montgomery, AL 36117 Phone: 334-271-2020 Fax: 334-271-2042 | |
Dr. Crisse Folds Bolton, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 540 Cotton Gin Rd, Montgomery, AL 36117 Phone: 334-323-3610 Fax: 334-323-3629 | |
Dr. Doris Ann Appleby, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5783 Carmichael Pkwy, Montgomery Optometric Clinic, Pa, Montgomery, AL 36117 Phone: 334-271-2020 Fax: 334-271-2042 |